BRD2 and astrocytoma (excluding glioblastoma): Indeed, we investigate the lncRNA expression profiles in a sample set including 40 NAT samples and 130 astrocytoma samples across grades II-IV, while the lncRNA signatures established by other studies were only from a limited patient cohort, or were only specific to GBM, or were not associated with prognosis, or were just from statistical analysis by literature screen.